TCOLF welcomes two projects started in March that target neglected diseases.
Kaj Kreutzfeldt will focus her research on the identification of compounds that synergize with orally available beta-lactams, a class of antibiotic used for the treatment of bacterial infections that have not been, however, broadly used for the treatment of Tuberculosis. The project, led by Prof. Ehrt, has started at the Joan & Sanford Weill Medical College of Cornell University and will continue at the GSK´s Tres Cantos Medicines Development Campus in the coming months.
Kevin Neildé will optimize compounds that show selective efficacy against Trypanosoma cruzi, the causative agent of Chagas disease. The project, led by Pr. Baell (Monash University) and Dr Piggott (University of Western Australia), intends to address the weaknesses of the current therapies, that have adverse side-effects and that neither prevent the development of, nor can treat, chronic Chagas disease.
A more detailed project description can be found in the “research projects” section.